Xospata

Active Ingredient(s): Gilteritinib
FDA Approved: * November 28, 2018
Pharm Company: * ASTELLAS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Xospata Overview

Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.[6] It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor.[7] It was developed by Astellas Pharma. In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).[8] In November 2018, the ...

Read more Xospata Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gilteritinib

Recent Xospata Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Gilteritinib
  • Tablet: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Xospata: (1 result)

Sorted by National Drug Code
  • 0469-1425 Xospata 40 mg Oral Tablet by Astellas Pharma Us, Inc.

Other drugs which contain Gilteritinib or a similar ingredient: (1 result)